Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 21981559)

1.

The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.

Lamy A, Wang X, Gao P, Tong W, Gafni A, Dans A, Avezum A, Ferreira R, Young J, Yusuf S, Teo K; ONTARGET Investigators.

J Med Econ. 2011;14(6):792-7. doi: 10.3111/13696998.2011.627405. Epub 2011 Oct 10.

PMID:
21981559
2.

Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.

Verdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S.

Hypertension. 2015 Jan;65(1):108-14. doi: 10.1161/HYPERTENSIONAHA.114.04310. Epub 2014 Oct 20.

PMID:
25331850
3.

Systolic blood pressure target levels: evidence for benefits in stroke.

Lackland DT.

Hypertension. 2015 Jan;65(1):39-40. doi: 10.1161/HYPERTENSIONAHA.114.04486. Epub 2014 Oct 20. No abstract available.

PMID:
25331844
4.

Predicting patients with high risk of becoming high-cost healthcare users in Ontario (Canada).

Chechulin Y, Nazerian A, Rais S, Malikov K.

Healthc Policy. 2014 Feb;9(3):68-79.

5.

Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.

Foulquier S, Böhm M, Schmieder R, Sleight P, Teo K, Yusuf S, Schumacher H, Unger T.

J Hypertens. 2014 Jun;32(6):1334-41. doi: 10.1097/HJH.0000000000000154.

PMID:
24621807
6.

Large streamlined trials in cardiovascular disease.

Calvo G, McMurray JJ, Granger CB, Alonso-García Á, Armstrong P, Flather M, Gómez-Outes A, Pocock S, Stockbridge N, Svensson A, Van de Werf F.

Eur Heart J. 2014 Mar;35(9):544-8. doi: 10.1093/eurheartj/eht535. Epub 2014 Jan 2. No abstract available.

7.

Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.

Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S.

Am Heart J. 2013 Aug;166(2):306-314.e7. doi: 10.1016/j.ahj.2013.04.016. Epub 2013 Jun 24.

PMID:
23895814
8.

Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.

Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators.

Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234.

9.

Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).

Mancia G, Parati G, Bilo G, Gao P, Fagard R, Redon J, Czuriga I, Polák M, Ribeiro JM, Sanchez R, Trimarco B, Verdecchia P, van Mieghem W, Teo K, Sleight P, Yusuf S.

Hypertension. 2012 Dec;60(6):1400-6. doi: 10.1161/HYPERTENSIONAHA.112.199562. Epub 2012 Oct 15.

10.

Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).

Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T; ONTARGET/TRANSCEND Investigators.

Circulation. 2012 Aug 21;126(8):934-41. doi: 10.1161/CIRCULATIONAHA.111.086660. Epub 2012 Jul 24.

11.

[Critically appraised article].

Neumann I, Grassi B.

Rev Med Chil. 2012 Jan;140(1):117-20. doi: /S0034-98872012000100018. Epub 2012 Apr 12. Spanish.

12.

Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.

Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators.

J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51.

PMID:
22495138
13.

Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators.

J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040.

14.

Telmisartan for the reduction of cardiovascular morbidity and mortality.

Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G.

Expert Rev Clin Pharmacol. 2011 Mar;4(2):151-61. doi: 10.1586/ecp.10.141. Review.

PMID:
22115399
15.

Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.

Miesel A, Müller-Fielitz H, Jöhren O, Vogt FM, Raasch W.

Br J Pharmacol. 2012 Apr;165(8):2721-35. doi: 10.1111/j.1476-5381.2011.01726.x.

16.

Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).

Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S.

Circulation. 2011 Oct 18;124(16):1727-36. doi: 10.1161/CIRCULATIONAHA.110.008870. Epub 2011 Sep 26.

17.

Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.

Yu LT, Zhu J, Tan HQ, Wang GG, Teo KK, Liu LS.

Chin Med J (Engl). 2011 Jun;124(12):1763-8.

PMID:
21740829
18.

Telmisartan for the management of patients at high cardiovascular risk.

Ruilope LM.

Curr Med Res Opin. 2011 Aug;27(8):1673-82. doi: 10.1185/03007995.2011.597378. Epub 2011 Jun 30. Review.

PMID:
21718097
19.

New clinical concepts after the ONTARGET trial.

Ruilope LM, Segura J, Zamorano JL.

Expert Rev Cardiovasc Ther. 2011 Jun;9(6):685-9. doi: 10.1586/erc.11.52.

PMID:
21714599
20.

Telmisartan in high-risk cardiovascular patients. No need to change standard practice.

[No authors listed]

Prescrire Int. 2011 Jun;20(117):150.

PMID:
21678702
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk